Aligos TherapeuticsALGS
13F holders, Q1 2026 (March 31)1holders
1new positions
1sold out
$7.43avg. 13F price*
At the end of Q1 2026, 1 institutions reported holding Aligos Therapeutics Inc. (ALGS) in their 13F filings, unchanged from Q4 2025. 1 opened new positions and 1 sold out. The largest holder was Fortitude Family Office, LLC ($505).
- Company
- Aligos Therapeutics Inc.
- CUSIP
- 01626L105
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $505 |
| Exits | 1 | $1K |
All 13F filers, Q4 2025 → Q1 2026: 68 shares bought and 135 shares sold, net −67 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Fortitude Family Office, LLC | 0.00% | New | 68 | $505 |
"% of holder's portfolio" is ALGS's weight in each manager's 13F, not the share of Aligos Therapeutics Inc. the manager owns.